Skip to main content
OpenTrials
Active, not recruiting

NCT Number: NCT07835490

Telemonitoring of HFrEF Patients

The aim of this study is to find out whether remote health monitoring can help people with chronic heart failure.

For 3 months, some patients use a SiDLY CARE PRO electronic wristband. It measures their physical activity, blood oxygen level and heart rate every 15 minutes. The information is sent electronically to a secure database.

The study includes two groups of patients. One group uses the wristband and receives regular cardiology care. The other group receives regular care without remote monitoring.

During the study, patients have three visits at the cardiology clinic. Their health, heart failure symptoms and treatment are assessed. They also complete short questionnaires about their quality of life and ability to perform everyday activities. The researchers compare the two groups to see whether remote monitoring is associated with better health and fewer hospital stays or deaths related to worsening heart failure.

The study began in February 2023 and is planned to continue until 31 December 2028.

Active, not recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

2nd Department of Cardiology, Medical University of Lodz, Poland

Lodz, 92-213, Poland

About this study

The aim of this study is to observe the impact of the 3-month telemonitoring intervention using an electronic wristband measuring physical activity, peripheral capillary oxygen saturation and heart rate (HR) in the population of clinically stable patients with chronic heart failure with reduced ejection fraction (HFrEF), compared with the control group of patients not undergoing this intervention.

The participants are recruited in the Clinical Ward of Cardiology and the outpatient cardiology clinic of the Central Teaching Hospital of the Medical University of Lodz, Poland. During the preliminary phase of the study (Frebruary 2023-May 2024) patients were consecutively recruited to the study arm, followed by the recruitment of patients to the control arm.

During the first study visit, the patients in the intervention group received an electronic wearable wristband SiDLY CARE PRO, which monitored their physical activity, peripheral capillary oxygen saturation and heart rate, taking measurements at 15-minute intervals and transmitting the results to a database. All the participants from both the study and the control group received standard care at the cardiology clinic. The study period covered the following 3 months, during which each patient underwent 3 outpatient visits. During each visit, a physical examination was performed, the history of medical events, a potential exacerbation of heart failure and possible changes in pharmacotherapy was obtained, and the following patient's functional assessment scales were completed: the Kansas City Cardiomyopathy Questionnaire-12 (KCCQ-12), the Visual Analogue Scale (VAS) and the 6 Activities of Daily Living Scale (6ADL). At V1, the Timed Up and Go Test (TUG) was also performed.

In both groups participating in the study, the incidence of a composite endpoint defined as death or hospitalisation for acute decompensated heart failure, its two components separately, HF-related hospitalisation equivalents as well as selected physical parameters and the results of the validated questionnaires mentioned above were analysed. In the study group, the data obtained by the telemonitoring wristbands were also analysed in subgroups specified on the basis of the time since the initiation of the intervention, the results of the KCCQ-12 and the occurrence of a composite endpoint.

After the initial phase of the study and acquisition of preliminary results, the prolongation of the study is planned until the 31st of December 2028 using the same protocol as the initial phase.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • provided written informed consent prior to any study specific procedures;
  • males and females aged >18 years old at the time of consent;
  • documented diagnosis of HFrEF prior to enrollment and optimally treated with pharmacological and/or device therapy;
  • left ventricular ejection fraction ≤40% in a transthoracic echocardiogram from the last 12 months before recruitment;
  • NYHA class II-III.

Exclusion criteria

  • acute or decompensated heart failure;
  • the primary cause of heart failure in the form of active myocarditis, constrictive pericarditis or a valvular heart disease that has not been treated by interventional or surgical means, as defined by the ESC guidelines;
  • myocardial infarction, unstable angina, stroke or transient ischemic attack, coronary revascularization by percutaneous coronary intervention or coronary artery bypass graft, valve replacement surgery or ICD/CRT implantation within 4 weeks prior to study enrollment;
  • planned coronary revascularization by percutaneous coronary intervention or coronary artery bypass graft;
  • planned valve replacement surgery;
  • status after heart transplantation;
  • symptomatic bradycardia or third-degree atrioventricular block without a pacemaker;
  • a severe non-cardiovascular disease with a life expectancy of less than 1 year, or a patient condition precluding the performance of the procedures specified in the study protocol;
  • diagnosis of malignancy at the time of screening;
  • history of an allergic reaction to materials contained in the wristband.

Treatment and study plan

Telemonitoring wristband

Device

The intervention includes wearing an electronic wearable wristband SiDLY CARE PRO (SiDLY, Poland; medical device CE 0197 marking) for the study period of 3 months. The device monitors physical activity (pedometer), peripheral capillary oxygen saturation and heart rate, taking measurements at 15-minute intervals and transmitting the results to a database.

Each user of the device receives an instruction regarding its proper use and battery loading.

Other names: Electronic wristband, Telemonitoring

Primary outcomes

  1. The incidence of death

    Time frame: From enrollment to the end of follow-up at 3 months

    The incidence of death assessed in both study and control group

  2. The incidence of hospitalisation for acute decompensated heart failure or its equivalent

    Time frame: From enrollment to the end of follow-up at 3 months

    The incidence of hospitalisation for acute decompensated heart failure or its equivalent will be assessed in both study and control arm. The equivalent of hospitalisation is defined as the need for intravenous diuretic therapy, intravenous catecholamine infusion or passive oxygen therapy.

Secondary outcomes

  1. The number of participants with jugular vein congestion

    Time frame: At each study visit: visit 1 (day 0), visit 2 (day 30), visit 3 (day 60), visit 4 (day 90)

    The presence or not of the jugular vein congestion, assessed dichotomously (present/absent) on physical examination both in the study and the control group.

  2. The number of participants who needed an oral cardiac pharmacotherapy dose escalation

    Time frame: At study visits: visit 2 (day 30), visit 3 (day 60), visit 4 (day 90)

    The necessity for oral cardiac pharmacotherapy dose escalation defined as any uptitration of beta-adrenoceptor antagonists, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers or calcium channel blockers since the previous study visit and/or at the ongoing visit, assessed in both control and study group

  3. The Kansas City Cardiomyopathy Questionnaire-12 (KCCQ-12) outcomes

    Time frame: At each study visit: visit 1 (day 0), visit 2 (day 30), visit 3 (day 60), visit 4 (day 90)

    Completing the Kansas City Cardiomyopathy Questionnaire-12 (KCCQ-12) in both study and control group. The KCCQ-12 is a validated tool to assess the health status of HF patients, consisting of four domains evaluating physical limitations, the frequency of symptoms, social limitations and the quality of life. Each domain can range from 0 to 100 points, with higher scores indicating better health (fewer symptoms, fewer social and physical limitations, a better quality of life). The scores from each domain are transformed according to a predefined algorithm to derive an overall score (0-100).

  4. The number of participants with lung crepitations

    Time frame: At each study visit: visit 1 (day 0), visit 2 (day 30), visit 3 (day 60), visit 4 (day 90)

    The presence or not of the lung crepitations, assessed dichotomously (present/absent) on physical examination both in the study and the control group.

  5. The number of participants with pleural effusion

    Time frame: At each study visit: visit 1 (day 0), visit 2 (day 30), visit 3 (day 60), visit 4 (day 90)

    The presence or not of the pleural effusion, assessed dichotomously (present/absent) on physical examination both in the study and the control group.

  6. The number of participants with peripheral edema

    Time frame: At each study visit: visit 1 (day 0), visit 2 (day 30), visit 3 (day 60), visit 4 (day 90)

    The presence or not of the peripheral edema, assessed dichotomously (present/absent) on physical examination both in the study and the control group.

  7. The number of participants with hepatomegaly

    Time frame: At each study visit: visit 1 (day 0), visit 2 (day 30), visit 3 (day 60), visit 4 (day 90)

    The presence or not of the hepatomegaly, assessed dichotomously (present/absent) on physical examination both in the study and the control group.

  8. The number of participants with ascites

    Time frame: At each study visit: visit 1 (day 0), visit 2 (day 30), visit 3 (day 60), visit 4 (day 90)

    The presence or not of the ascites, assessed dichotomously (present/absent) on physical examination both in the study and the control group.

  9. The number of participants with orthopnea

    Time frame: At each study visit: visit 1 (day 0), visit 2 (day 30), visit 3 (day 60), visit 4 (day 90)

    The presence or not of the orthopnea, assessed dichotomously (present/absent) on the medical history-taking from participant both in the study and the control group.

  10. The number of participants who needed an oral diuretic initiation or dose escalation

    Time frame: At study visits: visit 2 (day 30), visit 3 (day 60), visit 4 (day 90)

    The necessity for oral diuretic initiation or dose escalation since the previous study visit and/or at the ongoing visit, assessed in both control and study group

  11. The Visual Analogue Scale (VAS) outcomes

    Time frame: At each study visit: visit 1 (day 0), visit 2 (day 30), visit 3 (day 60), visit 4 (day 90)

    Completing the Visual Analogue Scale (VAS) in both study and control group. The VAS consists of a 20-cm vertical axis with evenly spaced points ranging from 0 to 100. Patients were asked to indicate how well or poorly they perceived their overall health status at the time of assessment. A score of 0 represented the worst health state imaginable to the patient, whereas a score of 100 represented the best imaginable health state.

  12. The 6 Activities of Daily Living Scale (6ADL) outcomes

    Time frame: At each study visit: visit 1 (day 0), visit 2 (day 30), visit 3 (day 60), visit 4 (day 90)

    Completing the 6 Activities of Daily Living Scale (6ADL) in both study and control group. The 6ADL is a validated tool used to assess patients' independence or dependence in six activities of daily living: personal hygiene, dressing, toileting, mobility within the home, bladder and bowel continence, and feeding. The patient receives one point for each activity that they are able to perform independently. The total score constitutes the Katz Index, ranging from 0 to 6 points, with a score of 6 indicating complete independence and a score of 0 indicating complete dependence.

  13. The Timed Up and Go Test (TUG) outcomes

    Time frame: At visit 1 (day 0)

    Completing the Timed Up and Go Test (TUG)) in both study and control group. The TUG test is a tool used to assess the risk of falls in older adults. It measures, in seconds, the time required for a patient to rise from a seated position, walk three metres at their usual pace, turn around, return to the chair, and sit down again. Higher TUG times have been observed in older patients and in those with poorer quality of life and a more severe course of heart failure, a higher risk of balance impairment.

Other outcomes

  1. Change in the results of heart rate measured in the study group using the wristbands

    Time frame: Comparison of the periods between the study visits: visit 1-visit 2 (day 0-day 30), visit 2-visit 3 (day 30-day 60), visit 3-visit 4 (day 60-day 90) performed after the completion of the observation

    Comparison of the mean/median circadian results of heart rate measured in the study group with the use of telemonitoring wristbands, in relation to the time from the beginning of the intervention.

  2. Change in the results of peripheral capillary oxygen saturation measured in the study group using the wristbands

    Time frame: Comparison of the periods between the study visits: visit 1-visit 2 (day 0-day 30), visit 2-visit 3 (day 30-day 60), visit 3-visit 4 (day 60-day 90) performed after the completion of the observation

    Comparison of the mean/median circadian results of peripheral capillary oxygen saturation measured in the study group with the use of telemonitoring wristbands, in relation to the time from the beginning of the intervention.

  3. Change in the results of daily number of steps taken measured in the study group using the wristbands

    Time frame: Comparison of the periods between the study visits: visit 1-visit 2 (day 0-day 30), visit 2-visit 3 (day 30-day 60), visit 3-visit 4 (day 60-day 90) performed after the completion of the observation

    Comparison of the mean/median results of daily number of steps taken measured in the study group with the use of telemonitoring wristbands, in relation to the time from the beginning of the intervention.

Interested in participating?

Active, not recruiting

This study is active but is not currently recruiting participants.

Notify Me

Sponsors and collaborators

Lead sponsor

Medical University of Lodz

Other

Registry information

Official study title

Telemonitoring of Patients With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF)

Important dates

Study start
2023
Primary completion
2024
Study completion
2028
First posted
Sep 23, 2026
Registry last updated
Sep 25, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.